During the forecast period from 2012 - 2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and is expected to reach $43.3 billion by 2017 at a CAGR of 14.0% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations.
The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
The asthma drugs market is projected to reach US$ 34,136.10 million in 2028 from US$ 24,239.17 million in 2021; it is estimated to grow at a CAGR of 5.0 % during 2021–2028.
Download Free Sample@ https://bit.ly/2V5TWKe #Market #MarketAnalysis #Chemicals #ChemicalsAndMaterial Anti Asthma Drugs Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Anti Asthma Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Anti Asthma Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Anti Asthma Drugs market covering all important parameters.
Bharat Book presents the report on “Global Markets for Generic Drugs” (https://www.bharatbook.com/healthcare-market-research-reports-467698/global-generic-drugs3.html). It provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs.
The respiratory disorders market is forecast to rise from a value of $28.1 billion in 2015 to $46.6 billion in 2022, at a CAGR of 7.5%. To See Full Report @ http://bit.ly/2ggmcXp
This report studies Asthma Treatment Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
The global anti-asthmatics and copd drugs market was valued at about $33.4 billion in 2018 and is expected to grow to $42.01 billion at a CAGR of 5.9% through 2022. Read more at http://bit.ly/2MO6KQM
North America was the largest region in the respiratory diseases drugs market in 2017, accounting for 48% market share. Read Report https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report-2018
The global anti-asthmatics and COPD drugs market size is expected to grow from $80.73 billion in 2021 to $88.18 billion in 2022 at a compound annual growth rate (CAGR) of 9.2%.
The respiratory diseases drugs market expected to reach a value of nearly $53.18 billion by 2022, significantly growing at a CAGR of 6.1% during the forecast period. Read more at https://bit.ly/3dEqJgx
The major players covered in the global anti-asthmatics and copd drugs market are Novartis AG, Merck & Co, GlaxoSmithKline , Boehringer Ingelheim Gmbh,
The Business Research Company’s Anti-Asthmatics And COPD Drugs Global Market Report 2019 covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. http://bit.ly/2m00bAa
Anti-Asthmatics And COPD Drugs Global Market Report 2020 is the latest research report added to The Business Research Company database. The report is covered in 200 pages covering 5 major players in the industry.
Big Market Research “Asthma Drugs Market in the US” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2019. Visit for more info @ http://www.bigmarketresearch.com/asthma-drugs-in-the-us-2015-2019-market Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors.
The global pulmonary/respiratory drug delivery market is expected to reach USD 63.79 billion by 2025, from USD 38.63 billion in 2017 growing at a CAGR of 6.7% during the forecast period of 2018 to 2025.
A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy.
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.
The global animal vaccines market is in its growth phase and is estimated to be worth $5.8 billion in 2013. It is expected to grow at a healthy CAGR of 8.1% to reach $8.6 billion by 2018.
Fueled by the growing focus on patient safety and technological advancements, the healthcare/medical simulation industry has experienced significant growth over the past decade, except for the past 3 to 4 years, where the market witnessed slow growth due to the global recession.
Download Sample Brochure @ http://tinyurl.com/zrskcem Allergic rhinitis is caused by the interaction of airborne allergens with specific immunoglobulin E (IgE) type antibodies on the surface of mast cells. This interaction causes mast cells to release and synthesize chemicals, causing inflammation of the surrounding tissues. Typical symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion. Extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma may also occur. Allergic rhinitis is treated using medications such as antihistamines, intranasal corticosteroids, or immunotherapies. Alternative forms of treatment are also employed in certain cases.
Download Sample Brochure @ http://tinyurl.com/zrskcem Allergic rhinitis is caused by the interaction of airborne allergens with specific immunoglobulin E (IgE) type antibodies on the surface of mast cells. This interaction causes mast cells to release and synthesize chemicals, causing inflammation of the surrounding tissues. Typical symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion. Extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma may also occur. Allergic rhinitis is treated using medications such as antihistamines, intranasal corticosteroids, or immunotherapies. Alternative forms of treatment are also employed in certain cases.
Download Sample Brochure @ http://tinyurl.com/zrskcem Allergic rhinitis is caused by the interaction of airborne allergens with specific immunoglobulin E (IgE) type antibodies on the surface of mast cells. This interaction causes mast cells to release and synthesize chemicals, causing inflammation of the surrounding tissues. Typical symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion. Extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma may also occur. Allergic rhinitis is treated using medications such as antihistamines, intranasal corticosteroids, or immunotherapies. Alternative forms of treatment are also employed in certain cases.
Download Sample Brochure @ http://tinyurl.com/zrskcem Allergic rhinitis is caused by the interaction of airborne allergens with specific immunoglobulin E (IgE) type antibodies on the surface of mast cells. This interaction causes mast cells to release and synthesize chemicals, causing inflammation of the surrounding tissues. Typical symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion. Extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma may also occur. Allergic rhinitis is treated using medications such as antihistamines, intranasal corticosteroids, or immunotherapies. Alternative forms of treatment are also employed in certain cases.
Big Market Research, PharmaPoint: Global Asthma Drug Market Size, Share, Strategies, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities. Big Market Research added a new research report "PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023". Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade. The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children. Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
Global Preventive Asthma Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the global preventive asthma drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. See Full Report @ bit.ly/12yBegp
Adrenergic drugs, also named as sympathomimetic drugs stimulate a response from the adrenergic receptors. This drug is used to stimulate the sympathetic nervous system located in the chest and lower back region of the spinal cord. These drugs stimulate the chemical messenger epinephrine and norepinephrine from the adrenal gland, or replicate the action of these chemical messengers. There are five main categories of adrenergic receptors as α₁, α₂, β₁, β₂, and β₃. Adrenergic drugs are used to increase the breathing rate, heartbeat, sweating, urine flow, and prevent bleeding. There are three major types of adrenergic drugs most commonly used such as Bronchodilators, vasopressors, and cardiac stimulators. This drug is used in the treatment of various life-threatening conditions including chronic obstructive pulmonary diseases (COPD), asthma, cardiac arrest, shock, and allergic reactions.
Global nasal drug delivery technology market size is expected to reach $110.08 Bn by 2028 at a rate of 7.3%, segmented as by dosage form, nasal spray, nasal drops, nasal gels and ointments, nasal powders, other dosage forms
"According to HTF Market Intelligence, the Paracetamol market is expected to see a growth rate of 3.3% and may see market size of USD1,278 Million by 2029."
"According to HTF Market Intelligence, the Paracetamol market is expected to see a growth rate of 3.3% and may see market size of USD1,278 Million by 2029."
According to the latest research report by IMARC Group, The global COPD and asthma devices market size reached US$ 45.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 69.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032. More Info:- https://www.imarcgroup.com/copd-asthma-devices-market
Global Pulmonary Drug Delivery Systems Market is expected to grow at CAGR of 6.2% from 2017 to 2025. The report highlights the key trends, market outlook and the global scenario of the Global Pulmonary Drug Delivery
Nasal drug has been extensively used and due to its efficacy its popularity is rising. Research and development has helped in making it more effective with less and less harm. This report talks about different market aspect of Nasal Drug Delivery Technology. Market drivers that can affect its growth and Delvens' analyst view on this market.
The global drug delivery systems market is estimated to garner a modest revenue of by the end of 2033 by growing at a CAGR of ~10% over the forecast period, i.e., 2023 – 2033
The global gynecologists market was valued at $1263.4 billion in 2017. North America was the largest geographic region accounting for $603.9 billion or 47.8% of the global market. The USA was the largest country accounting for $506.6 billion or 40% of the global gynecologists market.
Allergic Conjunctivitis Market will exceed US$ 2 Billion mark by 2025. Allergic conjunctivitis unusually caused when a person’s eye comes in contact with an allergen (substances that cause allergies, like pollen, chemicals, dirt or mold spores) as the conjunctiva is prone to irritation from allergens. The eye becomes inflamed and sore. In conjunctivitis, the tissue (conjunctiva) that lines inside of the eyelid and the white of the eyeball that keeps the eyeball and eyelid moist became inflamed. For More Information: https://www.renub.com/allergic-conjunctivitis-market-p.php
Download sample brochure @ http://tinyurl.com/jeu5bak This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects.